Table 1.
Participant Baseline Variables, Stratified by Race
| Patient variable | All, n=3031 | Black, n=1467 | White, n=1564 | P value |
|---|---|---|---|---|
| Age, y | 58±11 | 58±11 | 59±11 | 0.003 |
| Female sex | 1375 (45%) | 750 (51%) | 625 (40%) | <0.001 |
| BMI, kg/m2 | 32±8 | 33±8 | 31±7 | <0.001 |
| eGFR, mL/min per 1.73 m2 | 45.1±15 | 43.8±15 | 46.3±15 | <0.001 |
| UACR, μg/mg, median [IQR] | 40 [8–342] | 78 [12–523] | 24 [6–211] | <0.001 |
| Hemoglobin, g/dL | 12.7±1.7 | 12.2±1.7 | 13.2±1.6 | <0.001 |
| Baseline IL‐6, pg/mL, median [IQR] | 1.9 [1.1–3.1] | 2.1 [1.3–3.4] | 1.6 [1.0–2.8] | <0.001 |
| TMPRSS6 rs855791 genotype | ||||
| GG | 1569 (52%) | 1070 (73%) | 499 (32%) | <0.001 |
| GA | 1122 (37%) | 366 (25%) | 756 (48%) | |
| AA | 340 (11%) | 31 (2%) | 309 (20%) | |
| Cholesterol, mg/dL | 182.8±44.0 | 185.9±46.0 | 179.9±41.9 | <0.001 |
| Current smoker | 427 (14%) | 279 (19%) | 148 (9%) | <0.001 |
| College graduate | 1003 (33%) | 250 (17%) | 753 (48%) | <0.001 |
| Hypertension | 2599 (86%) | 1364 (93%) | 1235 (79%) | <0.001 |
| Diabetes | 1383 (46%) | 756 (52%) | 627 (40%) | <0.001 |
| History of CVD | 1055 (35%) | 565 (39%) | 490 (31%) | <0.001 |
| ACEi/ARB | 2087 (69%) | 1044 (71%) | 1043 (67%) | 0.009 |
| Aspirin | 1347 (45%) | 627 (43%) | 720 (46%) | 0.08 |
| Diuretic | 1804 (60%) | 1013 (69%) | 791 (51%) | <0.001 |
| Outcomes | ||||
| Death | 903 (30%) | 492 (34%) | 411 (26%) | <0.001 |
| CVD composite | 891 (34%) | 507 (41%) | 384 (28%) | <0.001 |
| CKD progression | 988 (33%) | 612 (42%) | 376 (24%) | <0.001 |
| Hemoglobin decline | 1249 (41%) | 783 (53%) | 466 (30%) | <0.001 |
P values are based on χ2 for categorical variables or the Kruskal‐Wallis test for continuous variables. ACEi/ARB indicates angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker; BMI, body mass index; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; IL‐6, interleukin‐6; IQR, interquartile range; TMPRSS6, transmembrane serine protease 6 gene; and UACR, urine albumin to creatinine ratio.